1-8 of 8
Rochelle Bagatell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

Navin Pinto, Arlene Naranjo, Xiangming Ding, Fan F. Zhang, Emily Hibbitts, Rebekah Kennedy, Rachelle Tibbetts, Shannon Wong-Michalak, David W. Craig, Zarko Manojlovic, Michael D. Hogarty, Susan Kreissman, Rochelle Bagatell, Meredith S. Irwin, Julie R. Park, Shahab Asgharzadeh
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1546–1556.
https://doi.org/10.1158/1078-0432.CCR-22-3032
Published: 14 April 2023
View article titled, Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <em>MYCN</em> Amplification: A Children's Oncology Group (COG) Report
Open the PDF for Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <em>MYCN</em> Amplification: A Children's Oncology Group (COG) Report in another window
Includes: Supplementary data
Journal Articles

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm Smith, Barry L. Shulkin, Marguerite Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2179–2189.
https://doi.org/10.1158/1078-0432.CCR-20-3909
Published: 15 April 2021
View article titled, Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Open the PDF for Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, Araz Marachelian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6142–6149.
https://doi.org/10.1158/1078-0432.CCR-18-1381
Published: 13 December 2018
View article titled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study

Rochelle Bagatell, Lia Gore, Merrill J. Egorin, Richard Ho, Glenn Heller, Nichole Boucher, Eleanor G. Zuhowski, James A. Whitlock, Stephen P. Hunger, Aru Narendran, Howard M. Katzenstein, Robert J. Arceci, Jessica Boklan, Cynthia E. Herzog, Luke Whitesell, S. Percy Ivy, Tanya M. Trippett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1783–1788.
https://doi.org/10.1158/1078-0432.CCR-06-1892
Published: 15 March 2007
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study in another window
Journal Articles

A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study

Brenda J. Weigel, Susan M. Blaney, Joel M. Reid, Stephanie L. Safgren, Rochelle Bagatell, John Kersey, Joseph P. Neglia, S. Percy Ivy, Ashish M. Ingle, Luke Whitesell, Richard J. Gilbertson, Mark Krailo, Matthew Ames, Peter C. Adamson
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1789–1793.
https://doi.org/10.1158/1078-0432.CCR-06-2270
Published: 15 March 2007
View article titled, A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Open the PDF for A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study in another window
Journal Articles

Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors

Jason Beliakoff, Rochelle Bagatell, Gillian Paine-Murrieta, Charles W. Taylor, Anne E. Lykkesfeldt, Luke Whitesell
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4961–4971.
Published: 27 October 2003
View article titled, Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors
Open the PDF for Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors in another window
Journal Articles

Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer

Rochelle Bagatell, Omar Khan, Gillian Paine-Murrieta, Charles W. Taylor, Shiro Akinaga, Luke Whitesell
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2076–2084.
Published: 01 July 2001
View article titled, Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: <subtitle>A Ligand-independent Approach to Hormonal Therapy of Breast Cancer</subtitle>
Open the PDF for Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: <subtitle>A Ligand-independent Approach to Hormonal Therapy of Breast Cancer</subtitle> in another window
Journal Articles

Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp90-binding Agents

Rochelle Bagatell, Gillian D. Paine-Murrieta, Charles W. Taylor, Elizabeth J. Pulcini, Shiro Akinaga, Ivor J. Benjamin, Luke Whitesell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (8): 3312–3318.
Published: 01 August 2000
View article titled, Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp90-binding Agents
Open the PDF for Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp90-binding Agents in another window